Sarepta Therapeutics’ (SRPT) “Outperform” Rating Reiterated at Raymond James

Raymond James restated their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note published on Thursday morning, MarketBeat reports. The brokerage currently has a $150.00 target price on the biotechnology company’s stock.

Other equities analysts have also issued reports about the company. Robert W. Baird upped their target price on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an outperform rating in a report on Friday, June 21st. Morgan Stanley reissued an overweight rating and set a $165.00 price objective on shares of Sarepta Therapeutics in a report on Friday, June 21st. Needham & Company LLC reissued a buy rating and set a $235.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, June 27th. Barclays reduced their price objective on Sarepta Therapeutics from $226.00 to $203.00 and set an overweight rating for the company in a report on Thursday, August 8th. Finally, Leerink Partners increased their price objective on Sarepta Therapeutics from $165.00 to $230.00 and gave the company an outperform rating in a report on Monday, June 24th. Two equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus target price of $185.47.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $124.51 on Thursday. The company has a market cap of $11.77 billion, a PE ratio of 1,131.91 and a beta of 0.82. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $173.25. The business has a 50 day moving average price of $130.19 and a 200-day moving average price of $132.49. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.01 by $0.06. The firm had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The company’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.27) earnings per share. Equities analysts anticipate that Sarepta Therapeutics will post 1.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Michael Andrew Chambers purchased 37,038 shares of the stock in a transaction on Friday, August 16th. The shares were acquired at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the transaction, the director now directly owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of large investors have recently added to or reduced their stakes in SRPT. Mather Group LLC. purchased a new stake in Sarepta Therapeutics during the first quarter valued at about $28,000. Riggs Asset Managment Co. Inc. raised its position in Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 125 shares in the last quarter. Innealta Capital LLC purchased a new stake in Sarepta Therapeutics during the second quarter valued at about $31,000. New Covenant Trust Company N.A. purchased a new stake in Sarepta Therapeutics during the first quarter valued at about $32,000. Finally, GAMMA Investing LLC raised its position in Sarepta Therapeutics by 37.0% during the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 87 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.